fda compounding semaglutide enforcement november 2025 news 🚨 Moves to Permanently Shut Down Compounded GLP-1s The FDA is taking steps to eliminate large-scale of GLP-1 medications like and tirzepatide, signaling a major shift in how these The FDA has issued warning

All dosage adjustments at Set Point Medical Weight Loss Clinic are made under careful medical supervision to ensure your treatment is both safe and effective

Individuals who lose weight rapidly often face loose skin issues, making it crucial to remove excess skin surgically for a sculpted, toned chest and a more youthful appearance

Current MDL: MDL No

If your last blood panel was more than six months ago or if youve never had a comprehensive metabolic workup getting current results before starting is the standard of care

And we have seen just as many lawsuits by pharma companies against compounding GLP-1s, with the FDA also releasing a warning letter last month

Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors to promote weight loss and improve blood sugar control in obesity and type 2 diabetes